RETIFANLIMAB

Search structure
Synonyms:
Status: Phase 3
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: 2Y3T5IF01Z

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Programmed cell death protein 1 antagonist

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Carcinoma, Squamous Cell 4 D002294 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Esophageal Neoplasms 2 D004938 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Pancreatic Neoplasms 2 D010190 ClinicalTrials
Neuroendocrine Tumors 2 D018358 ClinicalTrials
Head and Neck Neoplasms 2 D006258 ClinicalTrials
Endometrial Neoplasms 2 D016889 ClinicalTrials
Glioblastoma 2 D005909 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Triple Negative Breast Neoplasms 2 D064726 ClinicalTrials
Urinary Bladder Neoplasms 2 D001749 ClinicalTrials
Malignant Carcinoid Syndrome 2 D008303 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Paraganglioma 2 D010235 ClinicalTrials
Breast Neoplasms 2 D001943 ClinicalTrials
Liposarcoma 2 D008080 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials
Carcinoma, Pancreatic Ductal 1 D021441 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL4298037
FDA SRS 2Y3T5IF01Z
CONTENTS